Skip to main content
. 2015 Feb 25;2(1):41–50. doi: 10.2217/mmt.14.30

Table 3. . PD-L1 expression and response rate.

  n PDL-1+ PDL-1- Ref.
Nivolumab, Topalian et al. 42 9/25 (36%) 0/17 (0%) [36]

Nivolumab, Weber et al. 44 8/12 (67%) 6/32 (19%) [39]

Nivolumab, Grosso et al. 34 7/16 (44%) 3/18 (17%) [37]

MPDL3280A, Hamid et al. 30 4/15 (27%) 3/15 (20%) [25]

Nivolumab/ipilimumab, Callahan et al. 27 4/10 (40%) 8/17 (47%) [40]